If HCC expresses SGLT2, glucose uptake by cancer cells could be reduced by SGLT2 inhibitors, thus inhibiting aerobic glycolysis and suppressing tumor growth (Figure 9). This evidence concerns the gene SLC5A2 and hepatocellular carcinoma.